Anti-TNF-a drugs for refractory inflammatory bowel disease: clinical- and cost-effectiveness analyses
Assasi N, Blackhouse G, Xie F, Gaebel K, Marshall J, Irvine EJ, Giacomini M, Robertson D, Campbell K, Hopkins R, Goeree R
Record ID 32008100445
English
Authors' recommendations:
Although infliximab and adalimumab have been shown to provide clinical benefit, the costs associated with these treatments could be perceived as high. Based on the incremental cost-utility findings from our primary economic evaluations, adalimumab and infliximab for the treatment of IBD may not be perceived to be a cost-effective use of health care resources.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/H0479_Anti_TNF_a_Drugs_for_Refractory_Inflammatory_Bowel_Disease_tr_e.pdf
Year Published:
2009
URL for published report:
http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/894
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Colitis, Ulcerative
- Immunologic Factors
- Tumor Necrosis Factor-alpha
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.